NEW FIXED COMBINATION (FOSTER) FOR LONG AND SAFE ASTHMA CONTROL



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

About the authors

N M Nenasheva

N M Nenasheva

Russian Medical Academy for Postgraduate Education

Russian Medical Academy for Postgraduate Education

References

  1. Haahtela T., Tuomisto L.E., Pietinalho A. et al. A 10 year asthma programme in Finland: major change for the better. Thorax. 2006, v. 61, p. 663-670.
  2. Fanta C.H. Asthma NEJM. 2009, v. 360, p. 1002-1014.
  3. Szefler S.J., Martin R.J., King T.S. et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J. Allergy Clin. Immunol. 2002, v. 109, p. 410-418.
  4. Lemanske R.F. Jr., Sorkness C.A., Mauger E.A. et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA. 2001, v. 285, p. 2594-2603.
  5. Bateman E.D., Boushey H., Bousquet J. et al. GOAL Investigators Group. Can guideline-de? ned asthma control be achieved? The Gaining Optimal Asthma controL study. Am.
  6. J. Respir. Crit. Care Med. 2004, v. 170, p. 836-844. Глобальная стратегия лечения и профилактики бронхиальной астмы (GINA), пересмотр 2006 г., пер. с английского, М. Атмосфера. 2007.
  7. Rabe K.F., Atienza T., Magyar P. et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet. 2006, v. 368, p. 744-753.
  8. Barnes P.J. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur. Respir. J. 2002, v. 19, p. 182-191.
  9. Razzeti R., Bergamaschi M., Villetti G. et al. Formoterol and beclomethasone dipropionate interact positively in antagonizing brochoconstriction and inflammation in the lung. Pharmacol Res 2007;55(5):426-432
  10. Profita M., Gagliardo R., Di Giorgi R. et al. Biochemical interaction between effects of beclomethasone dipropionate and salbutamol or formoterol in sputum cells from mild to moderate asthmatics. Allergy. 2005, v. 60 (3), p. 323-329.
  11. Barnes P.J. Inhaled glucocorticoids for asthma. N. Engl. J. Med. 1995, v. 332, p. 868-875.
  12. Ganderton D., Lewis D., Davies R. et al. Modulite: a means of designing the aerosolos generated by pressurized metered dose inhalers. Respire Med. 2002, v. 96 (Suppl. D), p. 3-8.
  13. Fabbri L.M., Nicolini G., Olivery D. et al. Inhaled beclome-tasone dipropionate/formoterol extrafine fixed combination in the treatment of asthma: evidence and future perspectives. Expert. Opinion Pharmacother. 2008, v. 9, p. 479-490.
  14. Martin R.J. Therapeutic significance of distal airway inflammation in asthma. J. Allergy Clin. Immunol. 2002, v. 109 (Suppl 2), p. 447-460.
  15. Kraft M., Djukanovic R., Wilson S. et al. Alveolar tissue inflammation in asthma. Am. J. Respir. Crit. Care Med. 1996, v. 154, p. 1505-1510.
  16. Nicolini G., Scichilone N., Bizzi A. et al. Beclomethasone/ formoterol fixed combination for the management of asthma: patient considerations. Therapeutics and Clinical Risk Management. 2008, v. 4 (5), p. 496-504.
  17. Mariotti F., Poli G., Acerbi D. et al. Lung deposition of BDP/ formoterol HFA pMDI in healthy volunteers, asthmatic and COPD patients [abstract]. Poster presented at the VIII UIP National congress, Florence, 4-7 Dec 2007.
  18. Poli G., Acerbi D., Nollevaux F. Pharmacokinetics and pharma-codynamics of a new beclometasone dipropionate and formoterol CFC-free fixed combination in healthy volunteers. Eur Respir J. 2006, v. 28 (Suppl. 50), p. 3869 (Abstract).
  19. Piccinno A., Borrill Z., Poli G. et al. Tolerability of high cumu-lative doses of a new fixed combination of beclometasone dipropionate/ formoterol in asthmatic patients. Eur. Respir. J. 2006, v. 28 (Suppl 50), p. 1815 (Abstract).
  20. Rigamonti E., Kottakis I., Pelc M. et al. Comparison of a new extrafine beclometasone dipropionate HFA 134a-formulated pMDI with a standard BDP CFC pMDI in adults with moderate persistent asthma. Eur. Respir. J. 2006, v. 28 (Suppl 50), p 1236 (Abstract).
  21. Huchon G., Magnussen H., Chuchalin A. et al. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respiratory Medicine. 2009, v. 103, p. 41-49.
  22. Papi A., Paggiaro P.L., Nicolini G. et al. Beclometasone/ formoterol versus budesonide/formoterol combination therapy in asthma. Eur. Respir. J. 2007, v. 29, p. 682-689.
  23. Papi A., Paggiaro P.L., Nicolini G. et al. Beclomethasone/ formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy. 2007, v. 62, p. 1182-1188.
  24. Bender D., Milgrom H., Rand C. Nonadherence in asthmatic patients: is there a solution to the problem? Ann. Allergy Asthma Immunol. 1997, v. 79, p. 177-186.
  25. Howell G. Nonadherence to medical therapy in asthma: risk factors, barriers, and strategies for improving. J. Asthma. 2008, v. 45, p. 723-729.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 1970



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies